Acrivon Therapeutics (ACRV) CDO receives 38,584-share RSU grant with staged vesting

Rhea-AI Filing Summary

Gamelin Erick reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics, Inc. reported that Chief Development Officer Erick Gamelin received an equity compensation grant in the form of restricted stock units. The award covers 38,584 shares of Common Stock at a stated price of $0.00 per share, reflecting a grant rather than a market purchase.

Each RSU represents a contingent right to receive one share of Common Stock. According to the vesting schedule, 16.67% of the RSUs will vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to his continuous service. Following this grant, Gamelin directly holds 52,992 shares of Common Stock.

Insights

Equity compensation analyst

Routine RSU grant to Acrivon executive with multi-year vesting.

The filing shows Chief Development Officer Erick Gamelin receiving 38,584 restricted stock units as compensation, at a price of $0.00 per share. This is a non-market, stock-based award, classified as an acquisition under transaction code A.

The footnote explains that 16.67% of the RSUs will vest on November 18, 2026, with the balance vesting in 10 substantially equal quarterly installments, conditioned on continuous service. This structure is typical for long-term incentives intended to align executive interests with shareholders over time.

After the grant, Gamelin directly holds 52,992 shares of Common Stock. There are no derivative holdings reported and no sales or dispositions in this filing, indicating a straightforward compensation-related equity increase rather than trading activity.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gamelin Erick

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	38,584	$0.00	--

Holdings After Transaction: Common Stock — 52,992 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 38,584 RSUs Grant price: $0.00 per share Post-grant holdings: 52,992 shares +3 more

6 metrics

RSU grant size 38,584 RSUs Equity award to Chief Development Officer

Grant price $0.00 per share Recorded award price for RSUs

Post-grant holdings 52,992 shares Common Stock directly held after transaction

Initial vesting portion 16.67% of RSUs Portion vesting on November 18, 2026

Remaining vesting tranches 10 quarterly installments Remaining RSUs vest after November 18, 2026

Transaction code A (Grant, award, or other acquisition) Non-derivative Common Stock transaction

Key Terms

restricted stock units ("RSUs"), vest, continuous service, Grant, award, or other acquisition

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vest financial

"Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continuous service financial

"in each case subject to the Reporting Person's continuous service through each such vesting date."

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gamelin Erick

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		A(1)		38,584	A	$0	52,992	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Acrivon Therapeutics (ACRV) disclose in this Form 4 filing?

Acrivon Therapeutics disclosed that Chief Development Officer Erick Gamelin received a grant of 38,584 restricted stock units. These RSUs are equity compensation and not open-market purchases, increasing his direct holdings to 52,992 shares of the company’s Common Stock after the award.

How many Acrivon Therapeutics (ACRV) shares were granted to Erick Gamelin?

Erick Gamelin was granted 38,584 restricted stock units, each representing one share of Acrivon Therapeutics Common Stock. The grant price is recorded as $0.00 per share, reflecting stock-based compensation rather than a cash purchase on the open market.

What is the vesting schedule for Erick Gamelin’s new ACRV restricted stock units?

Of Erick Gamelin’s 38,584 RSUs, 16.67% will vest on November 18, 2026. The remaining units vest in 10 substantially equal quarterly installments afterward, provided he remains in continuous service with Acrivon Therapeutics through each scheduled vesting date.

How many Acrivon Therapeutics (ACRV) shares does Erick Gamelin hold after this grant?

Following the RSU grant, Erick Gamelin directly holds 52,992 shares of Acrivon Therapeutics Common Stock. This total reflects the impact of the newly awarded 38,584 restricted stock units reported in the Form 4, with no sales or dispositions disclosed in this filing.

Is the ACRV Form 4 transaction a market purchase or a compensation grant?

The Form 4 transaction is a compensation grant, not a market purchase. It is coded as an “A” transaction, representing a grant or award acquisition of 38,584 restricted stock units at a stated price of $0.00 per share for Erick Gamelin.